BloombergSarepta Surges After U.S. Regulators Delay Ruling on DMD DrugBloombergSarepta Therapeutics Inc. surged in early trading after the biotechnology company said U.S. regulators had delayed ruling on its drug for a deadly muscle disease, raising hopes that the therapy could be approved. The Food and Drug Administration ...Sarepta Saga Drags On as FDA Delays Decision on Duchenne DrugXconomyFDA Is Said to Delay Decision on Duchenne Muscular Dystrophy DrugNew York TimesFDA delays decision on Sarepta's muscle-wasting disorder drugReutersFierceBiotech -CNBC -Bidness ETC -StreetInsider.comall 50 news articles »